Nov 13,2024

Blue Circle Health Expands to Delaware and Ohio to Address Health System Barriers to Type 1 Diabetes Care and Education

Blue Circle Health, a nonprofit focused on improving outcomes for people with type 1 diabetes (T1D), has expanded its telehealth care, education, and support program to Delaware and Ohio. The program, already active in Florida, Maine, and Vermont, offers personalized care plans, including endocrinology support, diabetes education, peer support, and insurance navigation. Blue Circle Health aims to address the challenges T1D patients face in accessing care, medications, and supplies, with services provided at no cost. The program has supported over 450 adults with T1D since January 2024 and is designed to empower individuals to manage their condition effectively.

#telehealth

View Analyst & Ambassador Comments
Go to original news
Nov 13,2024

Beta Bionics Announces Closing of a $60 Million Series E Financing

Beta Bionics has successfully closed a $60 million Series E financing round, led by Wellington Management, with participation from existing investors including Eventide Asset Management and Sands Capital. The funding will support the commercialization of Beta Bionics' iLet Bionic Pancreas, an autonomous insulin delivery system that simplifies diabetes management by automatically determining insulin doses without the need for carb counting or insulin adjustments. The company aims to improve health outcomes and quality of life for people with diabetes and other glycemic conditions.

FUNDING STAGE
View Analyst & Ambassador Comments
Go to original news
Nov 07,2024

embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell

Embecta Corp. (Nasdaq: EMBC), a global diabetes care company, will ring the Nasdaq Closing Bell today in honor of National Diabetes Awareness Month. The event highlights the strength and individuality of people living with diabetes, with advocacy groups like ADCES, Beyond Type 1, and others joining in the celebration. Embecta, which has been supporting people with diabetes since 1924, remains committed to improving lives through innovative insulin delivery solutions, partnerships, and education. CEO Devdatt Kurdikar emphasized the importance of focusing on holistic well-being and ensuring diabetes doesn't limit anyone’s potential. The ceremony will be streamed live via Nasdaq’s Facebook page and shared on embecta's social media.

View Analyst & Ambassador Comments
Go to original news
Nov 04,2024

Omada Health Publishes Findings from Consumer Survey of GLP-1 Users

Omada Health released findings from a survey of 1,000 non-Omada members to explore the experiences of individuals taking GLP-1 medications for weight loss. The survey revealed that 78% of participants discussed lifestyle changes with their healthcare provider before or during their GLP-1 prescription, and 82% said their weight affected their emotional health prior to starting the medication. However, 65% of those who discontinued GLP-1s experienced anxiety, stress, or depression, with over three-quarters regaining weight. Access and cost challenges were major barriers to medication persistence, with 35% discontinuing due to out-of-pocket costs. The survey emphasized the need for additional behavior change support alongside GLP-1s to achieve sustained weight health outcomes. Omada's findings align with real-world data from its own programs, highlighting the importance of combining medication with lifestyle changes for long-term success.

View Analyst & Ambassador Comments
Go to original news
Nov 07,2024

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)

Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, reported strong financial results for the third quarter of 2024, with revenue of $543.9 million, a 25.7% increase compared to the prior year. Omnipod revenue reached $533.6 million, driven by both U.S. and international growth. The company’s Omnipod 5, the first automated insulin delivery system for both type 1 and type 2 diabetes, received FDA clearance for type 2 diabetes, further expanding its market. Insulet also launched the Omnipod 5 App and saw Omnipod named the top insulin pump for new users in Europe.

View Analyst & Ambassador Comments
Go to original news
May 11,2024 TOP STORY

Scan & Save: Easily monitor blood sugar levels

Beurer has launched a new “Scan & Save” feature within its “beurer HealthManager Pro” app to simplify blood sugar management for diabetics. Released in alignment with World Diabetes Day on November 14, 2024, this tool allows users to easily scan and digitally record blood glucose levels with their smartphone camera, addressing a key need for individuals using non-Bluetooth Beurer blood glucose meters. This update streamlines blood sugar tracking by eliminating the need for manual input, making diabetes management more accurate and accessible.

PRODUCT

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Nov 05,2024

Medtronic to announce financial results for its second quarter of fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today that it will release its financial results for the second quarter of fiscal year 2025 on Tuesday, November 19, 2024. The news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The release will provide a summary of the company's financial performance for the second quarter, which ended on Friday, October 25, 2024.

View Analyst & Ambassador Comments
Go to original news
Nov 04,2024

LATE-BREAKING DATA SHOWS SUSTAINED BENEFITS OF ABBOTT'S ESPRIT™ BTK SYSTEM FOR PEOPLE BATTLING PERIPHERAL ARTERY DISEASE BELOW THE KNEE

Abbott announced two-year results from its LIFE-BTK clinical trial, showing strong outcomes for its Esprit™ BTK Everolimus Eluting Resorbable Scaffold System, an FDA-approved dissolvable stent designed to treat severe peripheral artery disease (PAD) below the knee. The data demonstrated that 90.3% of patients treated with the Esprit BTK System did not require repeat procedures at 24 months, showing greater durability and reduced re-closure rates compared to traditional balloon angioplasty. The trial, presented at VIVA 2024, underscores Esprit BTK’s potential to reduce severe complications and improve quality of life for PAD patients. Abbott also launched a Post-Approval Study to further evaluate the system’s safety and effectiveness.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Nov 04,2024

Affidea Group partners with Reset Health to launch clinically-led digital weight loss and diabetes management solution across its network

Affidea, a leading provider of community-based healthcare in Europe, has announced a strategic collaboration with Reset Health to implement Roczen, a digital care model aimed at managing obesity and type 2 diabetes. This doctor-led, data-driven platform combines evidence-based interventions with advanced analytics to offer a comprehensive, digital solution for patients. Key features include personalized treatment plans, continuous health tracking, and direct communication between patients and healthcare providers. The partnership aligns with Affidea’s mission to expand its clinical services and address the growing demand for effective weight and diabetes management. Roczen will also offer access to GLP-1 medications, supporting chronic disease management. This collaboration underscores Affidea's commitment to providing accessible, patient-centered care while improving health outcomes for those affected by obesity and diabetes.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Feb 28,2024

Nova Scotia announces expanded coverage for insulin pumps and advanced glucose monitoring

Nova Scotia’s government has pledged $7.2 million to improve diabetes care by expanding access to digital diabetes devices, including continuous glucose monitors (CGMs) and insulin pumps, for residents managing type 1 and type 2 diabetes. The funding includes $5.9 million for CGM supplies through income-based and pharmacare programs and removes the age cap for insulin pump coverage, with an additional $1.3 million. These changes aim to assist approximately 4,000 people with glucose monitoring costs and provide 450 more individuals access to the Insulin Pump Program. This initiative aligns with JDRF Canada’s advocacy for broader access to life-saving diabetes technologies, supporting improved health outcomes and quality of life for those with diabetes in Nova Scotia.

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES